Publications

Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Keynote-040) : Subgroup Analysis by Pattern of Disease Recurrence

AuthID
P-00Z-C2R

Author(s)

Harrington, KJ

Cohen, EEW

Soulières, D

Dinis, J

Licitra, L

Ahn, MJ

Soria, A

Machiels, JP

Mach, N

Mehra, R

Burtness, B

Swaby, RF

Lin, J

Ge, J

Lerman, N

Le Tourneau, C

Document Type

Article

Year published

2023

Published

in ORAL ONCOLOGY, ISSN: 1368-8375

Volume: 147

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.oraloncology.2023.106587

Pubmed: 37925894

SCOPUS: 2-s2.0-85175709609

Wos: WOS:001108199800001

Source Identifiers

ISSN: 1368-8375

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Keynote-040) : Subgroup Analysis by Pattern of Disease Recurrence

Useful Links

Get Help

Federated Authentication (Click on the image)

Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Keynote-040) : Subgroup Analysis by Pattern of Disease Recurrence

Useful Links

Get Help